PFE vs PRAX

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Praxis Precision Medicines continues to advance its promising CNS pipeline, notably with the presumed NDA submission for PRAX-118 by end of 2025, a significant de-risking event reflected in its increased market cap to $8.97B. The company targets large, underserved markets (Essential Tremor, Epilepsies) with strong IP and novel mechanisms. While financial health remains a key watchpoint as a pre-co...